The role of steroids in acute spinal cord injury: An evidence-based analysis

Research output: Contribution to journalReview article

165 Citations (Scopus)

Abstract

Study Design. Literature review. Objectives. The purpose of this article is to review the available literature and formulate evidence-based recommendations for the use of methylprednisone in the setting of acute spinal cord injury (SCI). Summary of Background Data. Since the early 1990s, methylprednisolone has become widely prescribed for the treatment of acute SCI. Arguably, it has become a standard of care. Methods. Through an electronic database search strategy and by cross-reference with published literature, appropriate clinical studies were identified. They were reviewed in chronologic order with respect to study design, outcome measures, results, and conclusions. Results. Nine studies were identified that attempted to evaluate the role of steroids in nonpenetrating (blunt) spinal cord injury. Five of these were Class I clinical trials, and four were Class II studies. All of the studies failed to demonstrate improvement because of steroid administration in any of the a priori hypotheses testing. Although post hoc analyses were interesting, they failed to demonstrate consistent significant treatment effects. Conclusions. From an evidence-based approach, methylprednisolone cannot be recommended for routine use in acute nonpenetrating SCI. Prolonged administration of high-dose steroids (48 hours) may be harmful to the patient. Until more evidence is forthcoming, methylprednisolone should be considered to have investigational (unproven) status only.

Original languageEnglish (US)
Pages (from-to)S39-S46
JournalSpine
Volume26
Issue number24 SUPPL.
StatePublished - Dec 15 2001
Externally publishedYes

Fingerprint

Spinal Cord Injuries
Methylprednisolone
Steroids
Nonpenetrating Wounds
Standard of Care
Outcome Assessment (Health Care)
Clinical Trials
Databases
Therapeutics

Keywords

  • Evidence-based medicine
  • Methylprednisolone
  • NASCIS
  • Pharmacotherapy
  • Practice guidelines
  • Spinal cord injury
  • Steroids

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Clinical Neurology

Cite this

The role of steroids in acute spinal cord injury : An evidence-based analysis. / Hurlbert, R. J.

In: Spine, Vol. 26, No. 24 SUPPL., 15.12.2001, p. S39-S46.

Research output: Contribution to journalReview article

@article{049607e0c51943618ee531ba15c68840,
title = "The role of steroids in acute spinal cord injury: An evidence-based analysis",
abstract = "Study Design. Literature review. Objectives. The purpose of this article is to review the available literature and formulate evidence-based recommendations for the use of methylprednisone in the setting of acute spinal cord injury (SCI). Summary of Background Data. Since the early 1990s, methylprednisolone has become widely prescribed for the treatment of acute SCI. Arguably, it has become a standard of care. Methods. Through an electronic database search strategy and by cross-reference with published literature, appropriate clinical studies were identified. They were reviewed in chronologic order with respect to study design, outcome measures, results, and conclusions. Results. Nine studies were identified that attempted to evaluate the role of steroids in nonpenetrating (blunt) spinal cord injury. Five of these were Class I clinical trials, and four were Class II studies. All of the studies failed to demonstrate improvement because of steroid administration in any of the a priori hypotheses testing. Although post hoc analyses were interesting, they failed to demonstrate consistent significant treatment effects. Conclusions. From an evidence-based approach, methylprednisolone cannot be recommended for routine use in acute nonpenetrating SCI. Prolonged administration of high-dose steroids (48 hours) may be harmful to the patient. Until more evidence is forthcoming, methylprednisolone should be considered to have investigational (unproven) status only.",
keywords = "Evidence-based medicine, Methylprednisolone, NASCIS, Pharmacotherapy, Practice guidelines, Spinal cord injury, Steroids",
author = "Hurlbert, {R. J.}",
year = "2001",
month = "12",
day = "15",
language = "English (US)",
volume = "26",
pages = "S39--S46",
journal = "Spine",
issn = "0362-2436",
publisher = "Lippincott Williams and Wilkins",
number = "24 SUPPL.",

}

TY - JOUR

T1 - The role of steroids in acute spinal cord injury

T2 - An evidence-based analysis

AU - Hurlbert, R. J.

PY - 2001/12/15

Y1 - 2001/12/15

N2 - Study Design. Literature review. Objectives. The purpose of this article is to review the available literature and formulate evidence-based recommendations for the use of methylprednisone in the setting of acute spinal cord injury (SCI). Summary of Background Data. Since the early 1990s, methylprednisolone has become widely prescribed for the treatment of acute SCI. Arguably, it has become a standard of care. Methods. Through an electronic database search strategy and by cross-reference with published literature, appropriate clinical studies were identified. They were reviewed in chronologic order with respect to study design, outcome measures, results, and conclusions. Results. Nine studies were identified that attempted to evaluate the role of steroids in nonpenetrating (blunt) spinal cord injury. Five of these were Class I clinical trials, and four were Class II studies. All of the studies failed to demonstrate improvement because of steroid administration in any of the a priori hypotheses testing. Although post hoc analyses were interesting, they failed to demonstrate consistent significant treatment effects. Conclusions. From an evidence-based approach, methylprednisolone cannot be recommended for routine use in acute nonpenetrating SCI. Prolonged administration of high-dose steroids (48 hours) may be harmful to the patient. Until more evidence is forthcoming, methylprednisolone should be considered to have investigational (unproven) status only.

AB - Study Design. Literature review. Objectives. The purpose of this article is to review the available literature and formulate evidence-based recommendations for the use of methylprednisone in the setting of acute spinal cord injury (SCI). Summary of Background Data. Since the early 1990s, methylprednisolone has become widely prescribed for the treatment of acute SCI. Arguably, it has become a standard of care. Methods. Through an electronic database search strategy and by cross-reference with published literature, appropriate clinical studies were identified. They were reviewed in chronologic order with respect to study design, outcome measures, results, and conclusions. Results. Nine studies were identified that attempted to evaluate the role of steroids in nonpenetrating (blunt) spinal cord injury. Five of these were Class I clinical trials, and four were Class II studies. All of the studies failed to demonstrate improvement because of steroid administration in any of the a priori hypotheses testing. Although post hoc analyses were interesting, they failed to demonstrate consistent significant treatment effects. Conclusions. From an evidence-based approach, methylprednisolone cannot be recommended for routine use in acute nonpenetrating SCI. Prolonged administration of high-dose steroids (48 hours) may be harmful to the patient. Until more evidence is forthcoming, methylprednisolone should be considered to have investigational (unproven) status only.

KW - Evidence-based medicine

KW - Methylprednisolone

KW - NASCIS

KW - Pharmacotherapy

KW - Practice guidelines

KW - Spinal cord injury

KW - Steroids

UR - http://www.scopus.com/inward/record.url?scp=0035893891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035893891&partnerID=8YFLogxK

M3 - Review article

C2 - 11805608

AN - SCOPUS:0035893891

VL - 26

SP - S39-S46

JO - Spine

JF - Spine

SN - 0362-2436

IS - 24 SUPPL.

ER -